(Health Korea News / Ji-in Yoo) Dong-A ST announced that it will be presenting the non-clinical study results of ‘DA-7503’, which is being developed as a tau-targeting dementia treatment, at the Alzheimer’s Association International Conference (AAIC) held in Philadelphia, Pennsylvania, USA from the 28th of this month to August 1st (local time).
AAIC is the largest international conference in the field of Alzheimer’s disease. Every year, researchers, pharmaceutical and bio companies, including scholars from around the world, gather to share research results on Alzheimer’s disease and engage in various discussions.
At this conference, Dong-A ST will present a poster on the topic of ‘DA-7503’s effect on improving tauopathy and reducing tau in cerebrospinal fluid in Alzheimer’s disease and tauopathy disease models.’
Tau binds to microtubules of neurons and stabilizes the structure of neurons. In pathological conditions such as Alzheimer’s disease, mutated tau detaches from microtubules and forms tau oligomers and aggregates that exhibit neurotoxicity. Through this announcement, Dong-A ST plans to disclose data on the effects of ‘DA-7503’ on improving memory and cognitive function in animal models of Alzheimer’s disease and tauopathy, inhibition of tau aggregation and phosphorylation in the cerebral cortex and hippocampus, which are the main causes of Alzheimer’s disease, and reduction of tau in cerebrospinal fluid.
‘DA-7503’ is a small molecule compound tau aggregation inhibitor currently under development as a treatment for Alzheimer’s disease and tauopathy. It selectively acts on separated and modified tau, inhibits oligomer formation, and inhibits intracellular accumulation.
Dong-A ST received approval for the Phase 1 clinical trial plan (IND) for ‘DA-7503’ from the Ministry of Food and Drug Safety in April and began the trial a month later in May. The safety, tolerability, and pharmacodynamic characteristics of ‘DA-7503’ will be evaluated after single and repeated oral administration to 72 healthy adults and elderly people.
A Dong-A ST official said, “Through the results of this non-clinical study, we have proven that as the blood drug concentration increases after administration of ‘DA-7503,’ tau in the cerebrospinal fluid decreases dependently, and that ‘DA-7503’ has the possibility of a tau removal effect.”
Copyright © Health Korea News. Unauthorized reproduction and redistribution prohibited.
Source: www.hkn24.com
